Limits...
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.

Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, Koizumi W, Toh Y, Hara T, Miyata Y - Cancer Sci. (2014)

Bottom Line: The median progression-free survival and overall survival were 2.9 months (95% CI, 2.4-3.6) and 9.2 months (95% CI, 6.9-11.4), respectively.The most common grade 3/4 toxicities were neutropenia (49.1%), leucopenia (20.0%), lymphopenia (10.9%), and peripheral sensory neuropathy (23.6%).There were no treatment-related deaths.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Saitama Medical University International Medical Center, Hidaka-shi, Japan; Division of Medical Oncology, Department of Medicine, Showa University Hospital, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Waterfall plot of the best overall response to nanoparticle albumin-bound paclitaxel as second-line therapy in the full analysis set of patients with unresectable or recurrent gastric cancer. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317911&req=5

fig01: Waterfall plot of the best overall response to nanoparticle albumin-bound paclitaxel as second-line therapy in the full analysis set of patients with unresectable or recurrent gastric cancer. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.

Mentions: Overall responses in the 54 patients were reviewed and confirmed by the independent review committee (Table 2). One patient had a CR, 14 had PR, 17 had SD, and 21 had progressive disease. The ORR was 27.8% (95% CI, 16.5–41.6%), which exceeded the threshold response of 10% (Fig. 1). The median time to response was 36 days (range, 29–57 days).


Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.

Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, Koizumi W, Toh Y, Hara T, Miyata Y - Cancer Sci. (2014)

Waterfall plot of the best overall response to nanoparticle albumin-bound paclitaxel as second-line therapy in the full analysis set of patients with unresectable or recurrent gastric cancer. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317911&req=5

fig01: Waterfall plot of the best overall response to nanoparticle albumin-bound paclitaxel as second-line therapy in the full analysis set of patients with unresectable or recurrent gastric cancer. CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.
Mentions: Overall responses in the 54 patients were reviewed and confirmed by the independent review committee (Table 2). One patient had a CR, 14 had PR, 17 had SD, and 21 had progressive disease. The ORR was 27.8% (95% CI, 16.5–41.6%), which exceeded the threshold response of 10% (Fig. 1). The median time to response was 36 days (range, 29–57 days).

Bottom Line: The median progression-free survival and overall survival were 2.9 months (95% CI, 2.4-3.6) and 9.2 months (95% CI, 6.9-11.4), respectively.The most common grade 3/4 toxicities were neutropenia (49.1%), leucopenia (20.0%), lymphopenia (10.9%), and peripheral sensory neuropathy (23.6%).There were no treatment-related deaths.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Saitama Medical University International Medical Center, Hidaka-shi, Japan; Division of Medical Oncology, Department of Medicine, Showa University Hospital, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus